Distinctive features of immunostaining and mutational load in primary pulmonary enteric adenocarcinoma: Implications for differential diagnosis and immunotherapy

Journal of Translational Medicine

Volumn 16, Issue 1, 2018, Pages

  Chen, Ming ^a   Liu, Pu ^a   Yan, Feifei ^a   Xu, Suzhen ^a   Jiang, Qi ^a   Pan, Jingying ^a   He, Mengye ^a   Shen, Peng ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Immunohistochemistry; Immunotherapy; Primary pulmonary enteric adenocarcinoma; Targeted therapy; Tumor mutation burden

Indexed keywords

CYTOKERATIN 7; EPIDERMAL GROWTH FACTOR RECEPTOR; TRANSCRIPTION FACTOR CDX2; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; EGFR GENE; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENCE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MMR GENE; MUTATIONAL ANALYSIS; MUTATIONAL LOAD; ONCOGENE K RAS; PRIMARY PULMONARY ENTERIC ADENOCARCINOMA; PRIMARY TUMOR; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; WHOLE EXOME SEQUENCING; COLORECTAL TUMOR; DNA MUTATIONAL ANALYSIS; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MIDDLE AGED; MUTATION;

ADENOCARCINOMA OF LUNG; AGED; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MALE; MIDDLE AGED; MUTATION;

EID: 85044499275     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-018-1449-z     Document Type: Article

References (31)

1. Tsao MS, Fraser RS. Primary pulmonary adenocarcinoma with enteric differentiation. Cancer. 1991;68:1754-7.
2. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, Powell CA, Beer D, Riely G, Garg K, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc. 2011;8:381-5.
3. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol. 2015;10:1240-2.
4. Nottegar A, Tabbo F, Luchini C, Brunelli M, Bria E, Veronese N, Santo A, Cingarlini S, Gilioli E, Ogliosi C, et al. Pulmonary adenocarcinoma with enteric differentiation: immunohistochemistry and molecular morphology. Appl Immunohistochem Mol Morphol. 2016. https://doi.org/10.1097/PAI.0000000000000440.
5. Nottegar A, Tabbo F, Luchini C, Guerrera F, Gaudiano M, Bria E, Brunelli M, Chilosi M, Inghirami G. Pulmonary adenocarcinoma with enteric differentiation: dissecting oncogenic genes alterations with DNA sequencing and FISH analysis. Exp Mol Pathol. 2017;102:276-9.
6. Luchini C, Capelli P, Fassan M, Simbolo M, Mafficini A, Pedica F, Ruzzenente A, Guglielmi A, Corbo V, Scarpa A. Next-generation histopathologic diagnosis: a lesson from a hepatic carcinosarcoma. J Clin Oncol. 2014;32:e63-6.
7. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, An P, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31:1023-31.
8. Yousem SA. Pulmonary intestinal-type adenocarcinoma does not show enteric differentiation by immunohistochemical study. Mod Pathol. 2005;18:816-21.
9. Inamura K, Satoh Y, Okumura S, Nakagawa K, Tsuchiya E, Fukayama M, Ishikawa Y. Pulmonary adenocarcinomas with enteric differentiation: histologic and immunohistochemical characteristics compared with metastatic colorectal cancers and usual pulmonary adenocarcinomas. Am J Surg Pathol. 2005;29:660-5.
10. Li HC, Schmidt L, Greenson JK, Chang AC, Myers JL. Primary pulmonary adenocarcinoma with intestinal differentiation mimicking metastatic colorectal carcinoma: case report and review of literature. Am J Clin Pathol. 2009;131:129-33.
11. Hatanaka K, Tsuta K, Watanabe K, Sugino K, Uekusa T. Primary pulmonary adenocarcinoma with enteric differentiation resembling metastatic colorectal carcinoma: a report of the second case negative for cytokeratin 7. Pathol Res Pract. 2011;207:188-91.
12. Maeda R, Isowa N, Onuma H, Miura H. Pulmonary intestinal-type adenocarcinoma. Interact Cardiovasc Thorac Surg. 2008;7:349-51.
13. Lin D, Zhao Y, Li H, Xing X. Pulmonary enteric adenocarcinoma with villin brush border immunoreactivity: a case report and literature review. J Thorac Dis. 2013;5:E17-20.
14. Qureshi A, Furrukh M. Enteric adenocarcinoma lung: a rare presentation in an Omani woman. BMJ Case Rep. 2013. https://doi.org/10.1136/bcr-2012-007667.
15. Wang CX, Liu B, Wang YF, Zhang RS, Yu B, Lu ZF, Shi QL, Zhou XJ. Pulmonary enteric adenocarcinoma: a study of the clinicopathologic and molecular status of nine cases. Int J Clin Exp Pathol. 2014;7:1266-74.
16. Stojsic J, Kontic M, Subotic D, Popovic M, Tomasevic D, Lukic J. Intestinal type of lung adenocarcinoma in younger adults. Case Rep Pulmonol. 2014;2014:282196.
17. Laszlo T, Lacza A, Toth D, Molnar TF, Kalman E. Pulmonary enteric adenocarcinoma indistinguishable morphologically and immunohistologically from metastatic colorectal carcinoma. Histopathology. 2014;65:283-7.
18. Garajova I, Funel N, Fiorentino M, Agostini V, Ferracin M, Negrini M, Frassineti GL, Gavelli G, Frampton AE, Biasco G, Giovannetti E. MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy. Clin Epigenetics. 2015;7:129.
19. Metro G, Valtorta E, Siggillino A, Lauricella C, Cenci M, Ludovini V, Minenza E, Prosperi E, Ricciuti B, Rebonato A, et al. Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report. Ecancermedicalscience. 2015;9:559.
20. Handa Y, Kai Y, Ikeda T, Mukaida H, Egawa H, Kaneko M. Pulmonary enteric adenocarcinoma. Gen Thorac Cardiovasc Surg. 2016;64:749-51.
21. Lin LI, Xu CW, Zhang BO, Liu RR, Ge FJ, Zhao CH, Jia RU, Qin QH, Stojsic J, Wang Y, Xu JM. Clinicopathological observation of primary lung enteric adenocarcinoma and its response to chemotherapy: a case report and review of the literature. Exp Ther Med. 2016;11:201-7.
22. Matsushima J, Yazawa T, Suzuki M, Takahashi Y, Ota S, Nakajima T, Yoshino I, Yokose T, Inoue T, Kawahara K, Nakatani Y. Clinicopathological, immunohistochemical, and mutational analyses of pulmonary enteric adenocarcinoma: usefulness of SATB2 and beta-catenin immunostaining for differentiation from metastatic colorectal carcinoma. Hum Pathol. 2017;64:179-85.
23. Sun WW, Xu ZH, Wang CF, Wu F, Cao JM, Cui PJ, Huang W, Jin XL, Li B, Chen KM, et al. Pulmonary enteric adenocarcinoma with pancreatic metastasis: a case report. Oncol Lett. 2017;13:4651-6.
24. Bian TT, Zhao JL, Feng J, Zhang Q, Qian L, Liu J, Jiang DS. Combination of cadherin-17 and SATB homeobox 2 serves as potential optimal makers for the differential diagnosis of pulmonary enteric adenocarcinoma and metastatic colorectal adenocarcinoma. Oncotarget. 2017;8(38):63442.
25. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823-33.
26. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16:275-87.
27. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509-20.
28. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124-8.
29. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189-99.
30. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409-13.
31. Stadler ZK, Battaglin F, Middha S, Hechtman JF, Tran C, Cercek A, Yaeger R, Segal NH, Varghese AM, Reidy-Lagunes DL, et al. Reliable detection of mismatch repair deficiency in colorectal cancers using mutational load in next-generation sequencing panels. J Clin Oncol. 2016;34:2141-7.